Although further studies are needed to better define the systemic effects of BCP in animals, the promising results obtained so far in preclinical studies on models of metabolic and neurologic disorders strongly suggest that BCP constitute an attractive molecule for the treatment of diseases characterized by chronic inflammation. This evidence concerns the gene OPN1SW and inflammatory response.